Latest filing published 09 Sept 2025 for Teva Pharmaceutical Industries Ltd, €18k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +99.8%Entry US$14.32 · Close at T+90 US$28.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David R. McAvoy: trading record in brief
This profile gathers the share dealings of David R. McAvoy across 3 companies, led by Fresh Tracks Therapeutics, Inc., Teva Pharmaceutical Industries Ltd and Endocyte Inc. We count 16 filings; the first trade dates from 21 December 2018 and the latest from 5 September 2025.
The open-market side counts 7 purchases for €62k alongside 2 sales for €72k. The totals do not cover 1 filing with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 2 share grants and 3 option exercises. 2025 to date brings 1 purchase and 2 sales.
A typical purchase (the median) is worth €11k. Of 6 purchases, 5 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The record was last updated on 9 September 2025 with an open-market purchase (€18k) in Teva Pharmaceutical Industries Ltd. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to David R. McAvoy
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,113 shares@ US$18.8572100.0% of flowOrdinary SharesSEC:0000950170-25-113800:0Canonical exit: 4 Dec 2025 (T+90)
- 3,150 shares@ US$15.7352.3% of flowOrdinary SharesSEC:0000950170-25-034670:1
- 1,677 shares@ US$15.9127.8% of flowOrdinary SharesSEC:0000950170-25-034670:2
- 16,741 sharesOrdinary SharesSEC:0000950170-25-034670:0
- 7,358 shares@ US$0.979811.7% of flowCommon StockSEC:0001628280-23-033914:1
- 20,000 sharesCommon StockSEC:0001628280-23-033914:0
- 18,124 shares@ US$0.669745.7% of flowCommon StockSEC:0000819050-21-000124:0Canonical exit: 21 Oct 2021 (T+90)
- 7,980 shares@ US$0.8010.1% of flowCommon StockSEC:0001062993-21-004867:1Canonical exit: 15 Aug 2021 (T+90)
- 18,622 shares@ US$0.8054.3% of flowCommon StockSEC:0001062993-21-004867:0Canonical exit: 15 Aug 2021 (T+90)
- 8,750 shares@ US$1.1416.1% of flowCommon StockSEC:0001062993-21-002790:1
- 25,000 sharesCommon StockSEC:0001062993-21-002790:0
- 16,526 shares@ US$0.829830.1% of flowCommon StockSEC:0001062993-20-004584:0Canonical exit: 17 Dec 2020 (T+90)
- 6,000 shares@ US$0.839811.1% of flowCommon StockSEC:0001062993-20-004584:1Canonical exit: 17 Dec 2020 (T+90)
- 30,435 sharesCommon StockSEC:0000911916-20-000136:0Canonical exit: 20 Sept 2020 (T+90)
- 2,119 shares@ US$24.008.2% of flowCommon StockSEC:0001104659-18-074358:0
- 23,750 shares@ US$24.0091.8% of flowCommon StockSEC:0001104659-18-074358:1
16 of 16 declarations
